Background:Research has shown that the expression of UBD (Ubiquitin D) is effective in causing cancer. UBD
relationship between states with advanced stages of cancer cell differentiation and expression, which probably UBD
involved in the progression of carcinogenesis. Overexpression of UBD is related to p53, which subsequently progress
to cancer. The purpose of this study is evaluation of Ubiquitin D gene expression in leukemia patient as a biomarker
for detection of disease and its progression in patients as well.
Methods: In this study 100 patients with leukemia blood samples and 100 blood samples from healthy people between
ages 36 to 74 were collected. RNA is then extracted and cDNA synthesis to enzyme MMuLV and Random hexamer
primers Oligo dt was done. UBD specific primers were designed using Primer Express software and gene expression
levels UBD by ΔΔct (relative) were measured.
Results: UBD average increase gene expression in individuals less than 50 years equal to 5.82, P <0.0001 and in
more than is 50 years is 2.10, P <0.0001. 1.70 the lowest expression in CML and in ALL highest expression 7.97 than
their on normal average and the mean UBD gene overexpression in AML patients in this group of CLL equal to 3.21
and 4.94 (p-value <0.0001) was observed against.
Conclusion: UBD can be examined until perhaps as a biomarker for diagnosis of leukemia proposed to be used.
So, we can evaluate the expression of the genes used to diagnose leukemia. However, more studies than the current
application procedures, in cancer that has a lot of technical errors that were used in this study and prove its accuracy
and sensitivity is required.